Form 4: Ventyx Biosciences Director Sheila Gujrathi Acquires Stock Options

Director Sheila Gujrathi acquired 33,000 stock options in Ventyx Biosciences, Inc. at an exercise price of $3.285 on June 6, 2024.

Summary

• On June 6, 2024, Sheila Gujrathi, a director of Ventyx Biosciences, Inc., acquired 33,000 stock options.
• The exercise price for these options is $3.285.
• The options vest on the earlier of the one-year anniversary of the grant date or the day prior to the next Annual Meeting of the Issuer's stockholders, contingent upon continued service.
• The options expire on June 6, 2034.
• Gujrathi also has granted power of attorney to multiple individuals to act on her behalf in matters related to SEC filings.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It is neutral in tone and does not convey any specific positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but it does outline the vesting schedule for the acquired stock options.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings of company stock.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates